- Home
- HKPD vs BCAB Comparison
HKPD vs BCAB Comparison
Compare HKPD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKPD
- BCAB
- Stock Information
- Founded
- HKPD 2016
- BCAB 2007
- Country
- HKPD Hong Kong
- BCAB United States
- Employees
- HKPD N/A
- BCAB N/A
- Industry
- HKPD Other Pharmaceuticals
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- HKPD Health Care
- BCAB Health Care
- Exchange
- HKPD Nasdaq
- BCAB Nasdaq
- Market Cap
- HKPD 20.9M
- BCAB 22.3M
- IPO Year
- HKPD 2025
- BCAB 2020
- Fundamental
- Price
- HKPD $1.54
- BCAB $0.41
- Analyst Decision
- HKPD
- BCAB Buy
- Analyst Count
- HKPD 0
- BCAB 2
- Target Price
- HKPD N/A
- BCAB $1.00
- AVG Volume (30 Days)
- HKPD 3.3M
- BCAB 561.7K
- Earning Date
- HKPD 01-01-0001
- BCAB 08-07-2025
- Dividend Yield
- HKPD N/A
- BCAB N/A
- EPS Growth
- HKPD N/A
- BCAB N/A
- EPS
- HKPD 0.21
- BCAB N/A
- Revenue
- HKPD $20,770,344.00
- BCAB $11,000,000.00
- Revenue This Year
- HKPD N/A
- BCAB N/A
- Revenue Next Year
- HKPD N/A
- BCAB N/A
- P/E Ratio
- HKPD $7.21
- BCAB N/A
- Revenue Growth
- HKPD 32.91
- BCAB N/A
- 52 Week Low
- HKPD $0.81
- BCAB $0.24
- 52 Week High
- HKPD $3.79
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- HKPD N/A
- BCAB 44.32
- Support Level
- HKPD N/A
- BCAB $0.38
- Resistance Level
- HKPD N/A
- BCAB $0.46
- Average True Range (ATR)
- HKPD 0.00
- BCAB 0.06
- MACD
- HKPD 0.00
- BCAB -0.01
- Stochastic Oscillator
- HKPD 0.00
- BCAB 9.36
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.